Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Elacestrant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 1/20 | 1.00 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 9/20 | 0.38 |
| ▸ | DRD3 | P35462 | 9/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elacestrant SCHEMBL229432 | 1.00 | ESR1 (1.00) | ESR1ESR2CYP26A1ADRA1DADRA1A | |
| Elacestrant SCHEMBL29359701 | 1.00 | ESR1 (1.00) | ESR1ESR2CYP26A1ADRA1DADRA1A | |
| Elacestrant SCHEMBL2636500 | 0.99 | ESR1 (0.98) | ESR1ESR2CYP26A1ADRA1DADRA1A | |
| Elacestrant SCHEMBL29580748 | 0.99 | ESR1 (0.98) | ESR1ESR2CYP26A1ADRA1DADRA1A | |
| Elacestrant SCHEMBL2636657 | 0.99 | ESR1 (0.98) | ESR1ESR2CYP26A1ADRA1DADRA1A | |
| SCHEMBL227067 | 0.94 | ESR1 (0.89) | ESR1ESR2CYP26A1ADRA1DADRA1A | |
| SCHEMBL227068 | 0.94 | ESR1 (0.89) | ESR1ESR2CYP26A1ADRA1DADRA1A | |
| SCHEMBL22355580 | 0.94 | ESR1 (0.89) | ESR1ESR2CYP26A1ADRA1DADRA1A | |
| SCHEMBL228641 | 0.93 | ESR1 (0.86) | ESR1ESR2CYP26A1ADRA1DADRA1A | |
| SCHEMBL227456 | 0.93 | ESR1 (0.86) | ESR1ESR2CYP26A1ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007620-A1 | METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS | UNIV DUKE (US) | 2026-01-08 | — | — | US | claimed |
| EP-3834824-B1 | TREATMENT OF AN ESTROGEN RECEPTOR POSITIVE BREAST CANCER USING A SELECTIVE ESTROGEN RECEPTOR MODULATOR | UNIV DUKE (US) | 2025-10-22 | — | — | EP | claimed |
| US-20250262214-A1 | INTERMITTENT DOSING REGIMEN FOR AZENOSERTIB IN TREATING CANCER | ZENO MANAGEMENT, INC. | 2025-08-21 | — | — | US | claimed |
| US-20250205180-A1 | METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS | DUKE UNIVERSITY | 2025-06-26 | — | — | US | claimed |
| US-20240325397-A1 | USE OF COMBINATION THERAPY FOR TREATING CANCER | RECURIUM IP HOLDINGS, LLC | 2024-10-03 | — | — | US | claimed |
| US-20240197654-A1 | METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS | DUKE UNIVERSITY | 2024-06-20 | — | — | US | claimed |
| WO-2024102650-A1 | INTERMITTENT DOSING REGIMEN FOR AZENOSERTIB IN TREATING CANCER | ZENO MANAGEMENT, INC. (US) | 2024-05-16 | — | — | WO | claimed |
| US-11951080-B2 | Method of treating cancer using selective estrogen receptor modulators | DUKE UNIVERSITY (US) | 2024-04-09 | — | — | US | claimed |
| WO-2023172909-A1 | COMPOSITIONS COMPRISING ANTI-PROGESTINS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | CONTEXT BIOPHARMA INC. (US) | 2023-09-14 | — | — | WO | claimed |
| WO-2023114871-A1 | USE OF COMBINATION THERAPY FOR TREATING CANCER | RECURIUM IP HOLDINGS, LLC (US) | 2023-06-22 | — | — | WO | claimed |
| EP-3122426-A1 | METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS | Duke University (US) | 2017-02-01 | — | — | EP | claimed |
| US-20160324808-A1 | METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. | 2016-11-10 | — | — | US | claimed |
| US-9421264-B2 | Method of treating cancer using selective estrogen receptor modulators | DUKE UNIVERSITY (US) | 2016-08-23 | — | — | US | claimed |
| US-20150274640-A1 | METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. | 2015-10-01 | — | — | US | claimed |
| WO-2015149045-A1 | METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS | DUKE UNIVERSITY (US) | 2015-10-01 | — | — | WO | claimed |
| US-8933130-B2 | Treatment of vasomotor symptoms with selective estrogen receptor modulators | RADIUS HEALTH, INC. (US) | 2015-01-13 | — | — | US | claimed |
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | claimed |
| EP-2037905-B1 | TREATMENT OF VASOMOTOR SYMPTOMS WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2013-05-01 | — | — | EP | claimed |
| US-20100105733-A1 | Treatment of vasomotor symptoms with selective estrogen receptor modulators | RADIUS HEALTH, INC. | 2010-04-29 | — | — | US | claimed |
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007620-A1 | METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS | ESRRA, ESRRG, ESRRB | ESR1 21/4885ESR2 4/4885CYP26A1 235/4885 |
| US-11951080-B2 | Method of treating cancer using selective estrogen receptor modulators | ESRRG, ESRRB, ESR2 | ESR1 6/4885ESR2 3/4885CYP26A1 66/4885 |
| US-20250205180-A1 | METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS | ESRRG, ESRRB, ESR2 | ESR1 6/4885ESR2 3/4885CYP26A1 66/4885 |
| US-20150274640-A1 | METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS | ESRRG, ESRRB, ESR2 | ESR1 6/4885ESR2 3/4885CYP26A1 66/4885 |
| US-20240197654-A1 | METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS | ESRRG, ESRRB, ESR2 | ESR1 6/4885ESR2 3/4885CYP26A1 66/4885 |
| US-20160324808-A1 | METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS | ESRRG, ESRRB, ESR2 | ESR1 6/4885ESR2 3/4885CYP26A1 66/4885 |
| US-20100105733-A1 | Treatment of vasomotor symptoms with selective estrogen receptor modulators | GPER1, ESR1, SHBG | ESR1 2/4885ESR2 4/4885CYP26A1 180/4885 |
| US-20250262214-A1 | INTERMITTENT DOSING REGIMEN FOR AZENOSERTIB IN TREATING CANCER | ABL1, KRAS, JAK2 | ESR1 1262/4885ESR2 3322/4885CYP26A1 1064/4885 |
| US-20240325397-A1 | USE OF COMBINATION THERAPY FOR TREATING CANCER | TP53, TOP2A, MCL1 | ESR1 2289/4885ESR2 663/4885CYP26A1 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.